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Intermediate-Risk AML with FLT3-ITD or Wild-Type
NPM1 and CEBPA without FLT3-ITD
Ga€elle Laboure,1 Stephanie Dulucq,2 Myriam Labopin,3 Reza Tabrizi,1 Estelle Guerin,4
Arnaud Pigneux,1,6 Xavier Lafarge,5 Thibaut Leguay,1 Krimo Bouabdallah,1
Marie-Sarah Dilhuydy,1 Cedric Duclos,1 Axelle Lascaux,1 Gerald Marit,1,6
Franc¸ois-Xavier Mahon,2,6 Jean-Michel Boiron,5,6 No€el Milpied,1,6 Stephane Vigouroux1To investigate the roleof reduced-intensity allogeneic (RIC-allo) stemcell transplant (SCT)aspostremission ther-
apy in adult intermediate-risk patients with acute myelogenous leukemia (AML) with FLT3-ITD or wild-type
NPM1 and CEBPA without FLT3-ITD, we conducted a single-center retrospective study between January 2001
and December 2010. Sixty-six patients were included: 37 treated with RIC-alloSCTand 29 with nonallogeneic
SCT therapies. Both groups were comparable concerning age, WBC count at diagnosis, gender, karyotype, ge-
notype, and number of courses of chemotherapy to reach complete remission (CR1). Median follow-up after
CR1was 37months (range, 11-112 months) and 48months (range, 9-83 months) in the allo and no-allo groups,
respectively. In the allo versus no-allo groups, the 3-year cumulative incidence of relapse (CIR) rates were
25% 6 8% versus 61% 6 9%; P 5 .005. The 3-year nonrelapse mortality (NRM), overall survival (OS), and
relapse-free survival (RFS) were 22% 6 7% versus 4% 6 4% (P 5 .005), 52% 6 9% versus 44% 6 10%
(P 5 .75), and 53% 6 9% versus 35% 6 9% (P 5 .28), respectively. Multivariate analysis indicated that CIR
was reduced by allo (hazard ratio [HR], 0.32; P 5 .01). A landmark analysis performed at day 185 after CR1
confirmed a lower CIR after allo. RIC-allo reduces the risk of relapse, suggesting a potent graft-versus-
leukemia (GVL) effect in these patients at a high risk of relapse.
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oi.org/10.1016/j.bbmt.2012.06.012leukemia (IR-AML) in first complete remission
(CR1) is controversial and remains a domain of intense
investigation [1-4]. A recent meta-analysis of prospec-
tive clinical trials has reported a significant benefit of
myeloablative allo for relapse-free survival (RFS) and
overall survival (OS) [5]. The median age of patients
in most of these trials was in the 30s, and an equivalent
benefit in older patients remains uncertain. A
German-Austrian retrospective study has demon-
strated that genotypes defined by the mutational status
of FMS-like tyrosine kinase 3 (FLT3), nucleophos-
min1 (NPM1), and CCAAT/enhancer binding protein
a (CEBPA) genes were associated with the outcome
for cytogenetically normal AML [6]. The benefit of
allo was limited to the subgroup of patients with the
prognostically adverse genotype FLT3 internal
tandem duplication (FLT3-ITD) or the genotype con-
sisting of wild-typeNPM1 and CEBPA without FLT3-
ITD (triple-negative). In these patients, allo improved
RFS. It must be emphasized that patients were under1845
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HLA matched-related donor (MRD) after a myeloa-
blative conditioning regimen. As a consequence, the
benefit of reduced-intensity allo (RIC-allo) as postre-
mission therapy in older patients with IR-AML and
FLT3-ITD or a triple-negative genotype remains un-
certain. In an effort to further explore the role of allo
in this setting, we performed a retrospective study of
patients treated with RIC-allo or nonallogeneic SCT
therapies in the absence of a suitable donor. Our aim
was to compare both postremission strategies.MATERIALS AND METHODS
Selection of Patients
The selection criteria for inclusion in this study
were set to select a population of patients between
18 and 65 years of age, diagnosed with de novo
AML (except acute promyelocytic leukemia) between
January 2001 and December 2010 at our center. All
patient records were reviewed, and some patients
were excluded from the analysis as detailed in
Figure 1. AML with favorable or adverse karyotypes
were excluded. Patients transplanted in CR1 afterFigure 1. Selection of patients included in the study.a myeloablative conditioning regimen were also
excluded, as were patients who never reached com-
plete remission (CR). Genetic-risk groups were de-
fined according to the recommendations from an
international expert panel [7]. Patients diagnosed be-
fore 2007 at our center were not genotypically defined
at diagnosis, and those with available frozen leukemic
cells were retrospectively analyzed. Thus, patients
with a normal karyotype and either FLT3-ITD or
triple-negative genotype (intermediate-I group) were
included in the present study, as were patients with cy-
togenetic abnormalities not classified as favorable or
adverse and either FLT3-ITD or triple-negative geno-
type (intermediate-II group). We have included pa-
tients with cytogenetic abnormalities not classified as
favorable or adverse when associated with an adverse
genotype because there is some evidence that FLT3-
ITD and triple-negative genotype adversely affect
the outcome of these patients [7-9] as they do for
patients with a normal karyotype [6]. Before 2007,
our therapeutic strategy was to pursue allo in CR1
for patients with cytogenetically defined IR-AML.
From 2007, the same strategy was applied for
patients with IR-AML with either FLT3-ITD or
triple-negative genotype. Patients with cytogenetic
abnormalities not classified as favorable or adverse
and a favorable genotype (mutated NPM1 without
FLT3-ITD or mutated CEBPA) were not included in
our comparative study because we always chose to
treat them with nonallogeneic SCT therapies in
CR1 without looking for a donor. As a consequence,
the unique reason for not performing allo in our study
was the absence of a suitable donor at the time of CR1.
From 2001 to 2006, patients underwent transplanta-
tion only with MRDs. From 2007, patients underwent
transplantation in priority with MRD, then matched-
unrelated donor, and finally mismatched-unrelated
donor (C or DQB1) in the absence of MRD or
matched-unrelated donor. Cord blood units were
used from 2008 in the absence of any related or unre-
lated donor. Finally, to minimize potential biases fa-
voring patients who underwent transplantation,
patients ineligible for allo because of a poor perfor-
mance status or a severe comorbidity were excluded,
as were patients deceased or in relapse before the me-
dian time between CR1 and allo.Materials
Bone marrow samples were used whenever avail-
able. In all other cases, peripheral blood samples
were examined if the percentage of blasts in peripheral
blood was .25%. Genomic DNA was extracted from
mononuclear cells separated by Ficoll gradient. Geno-
mic DNA (gDNA) was extracted using a QIAamp
DNA Blood miniKit (Qiagen, Courtaboeuf, France),
according to the manufacturer’s protocol.
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Gene Mutations
The presence of FLT3-ITD and NPM1 gene mu-
tations was detected by capillary electrophoresis-
based fragment analysis after fluorescence labeled
PCR on gDNA. Primers 11F and 12R were used for
FLT3-ITD detection as previously described [10].
Forward primer 50-[HEX]TTCCATACATACTT
AAAACCAAGCA-30described by Boissel et al. [11]
and reverse primer 50-TTAACTCTCTGGTGGTA
GAATGAA-30 described by Falini et al. [12] were
used for NPM1 exon 12 mutations. Mutations of the
CEBPA gene were detected by gDNA PCR and
direct sequencing according to the method previously
described [13].
Patients’ Characteristics
Sixty-six patients were included. After CR1, 37were
treated with RIC-allo (allo group) and 29 with non-
allogeneic SCT therapies (no-allo group). The reasons
for choosing RIC instead of myeloablative conditioning
regimen were as follows: age$50 years (n5 32), num-
ber of courses of chemotherapy before allo$3 (n5 4),
and abnormal liver function tests (n 5 1). The median
age at diagnosis was 55 years (range, 19-64 years).There
were 33malepatients. Forty-three patients had anormal
karyotype and 23 had cytogenetic abnormalities not
classified as favorable or adverse. Forty-two patients
had a triple-negative genotype and 24 patients had the
FLT3-ITD. The median time between CR1 and allo
was 114 days (range, 24-295 days). Conditioning regi-
men combined fludarabine with an alkylating agent
(n5 27) or TBI2Gy (n5 10). The sources of stem cells
were peripheral blood (n5 32), bonemarrow (n5 1), or
cord blood (n 5 4). Donors were matched-related
(n5 18), matched-unrelated at the allele level (4 digits)
for HLA-A, B, C, DRB1, and DQB1 (n 5 11), or
mismatch-unrelated (C: n5 2 and DQB1: n 5 2, all at
the antigen level).
Statistical Analysis
Patient-related and disease-related variables of the
2 groups (receiving or not allo) were compared using
the chi-square statistic for categorical and the
Mann-Whitney test for continuous variables. Vari-
ables considered were allo (yes versus no), patient age
at diagnosis ($55 versus \55 years, because this is
the median age of the whole cohort), WBC count at
diagnosis (. versus\30,000/mL) [14], karyotype (nor-
mal versus abnormal), genotype (FLT3-ITD versus
triple-negative), number of courses of chemotherapy
to reach CR1 (1 versus$2), and year of CR1 (. versus
#2006). RFS after CR1was defined as survival without
evidence of relapse or progression. The nonrelapse
mortality (NRM) was defined as death while in CR.
Cumulative incidence curves were used for relapseincidence (RI) and NRM in a competing risks setting,
death in CR being a competing event for relapse. The
Gray test was used for univariate comparisons [15].
Probabilities of OS and RFS were calculated using
the Kaplan-Meier estimate [16]; the log-rank test was
used for univariate comparisons. In order to take into
account for delay before allo, we performed a landmark
analysis at day 185 after CR1. All factors studied were
included in the Cox proportional hazards [17] for OS
and RFS, and in a Fine-Gray model for RI and
NRM [18]. Given the retrospective design of the study,
and in order tominimize all possible biases, we decided
to adjust the comparison between the 2 groups (allo
versus no-allo) on all potential prognostic factors
even if not significant in our population. All tests
were 2-sided. The type I error rate was fixed at 0.05
for determination of factors associated with time-
to-event outcomes. Statistical analyses were performed
with the SPSS version 19 (IBM, Chicago, IL) and R
2.13.2 software packages (R Development Core
Team, Vienna, Austria).RESULTS
Comparison of Patients’ Characteristics
between Allo and No-Allo Groups
As shown inTable 1, both groups were comparable
concerning age, gender, WBC at diagnosis, propor-
tion of normal/abnormal karyotypes, proportion of
FLT3-ITD/triple-negative genotypes, and number of
courses of chemotherapy to reach CR1.Relapse and Survival
The median follow-up after CR1 was 37 months
(range, 11-112 months) in the allo group and 48
months (range, 9-83 months) in the no-allo group. In
the allo group, the median follow-up after transplanta-
tion was 30 months (range, 7-108 months). In the allo
versus no-allo groups, the 3-year OS were 52% 6 9%
versus 44%6 10%, P5 .75, and the 3-year RFS were
53% 6 9% versus 35% 6 9%, P 5 .28 (Figure 2).
Nineteen patients have died in the allo group from dis-
ease (n 5 9), infections (n 5 7; bacterial septic shock:
n 5 3; bacterial pneumonia: n 5 3; cytomegalovirus
colitis: n 5 1, with 5 patients having extensive chronic
graft-versus-host disease [GVHD] and 1 acute
[aGVHD] at the time of infection), aGVHD (n 5 2),
or suicide (n 5 1). Fourteen patients have died in the
no-allo group from disease (n 5 13) or infection
(n 5 1). Neither OS nor RFS were significantly influ-
enced by any of the studied variables in univariate or
multivariate analyses. In the allo versus no-allo groups,
the 3-year cumulative incidence of relapse (CIR) rates
were 25% 6 8% versus 61% 6 9%, P 5 .005
(Figure 3). In the allo group, 10 patients have relapsed
Table 1. Characteristics of Patients Included in the Study
Separated into Allo and No-Allo Groups
Variables
Allo
Group
n 5 37
No-Allo
Group
n 5 29 P Value
Age at diagnosis, years
Median (range) 56 (31-64) 54 (19-64) .50
Gender .08
Male 22 11
Female 15 18
WBC count >30,000/mL at diagnosis 11/37 11/29 .50
Karyotype .30
Normal 22 21
Abnormal 15 8
Genotype .20
FLT3-ITD 11 13
Triple-negative 26 16
Courses of chemotherapy to
reach CR1 (n)
1 versus $2
1 22 21 .30
2 12 8
3 3 0
Courses of chemotherapy
after CR1 (n)*
NA
0 8 0
1 15 3
2 11 6
$3 0 8
1 + autoSCT 3 8
2 + autoSCT 0 4
Allo indicates allogeneic; autoSCT, autologous stem cell transplantation;
NA, not applicable.
*Before allogeneic SCT in the allo group.
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after CR1. In the no-allo group, 18 patients have re-
lapsed at a median time of 8 months (range, 4-44
months) after CR1. Six of them were treated with
allo in CR2. The other patients did not undergo trans-
plantation mainly because of inability to reach CR2
(n 5 7), absence of a donor (n 5 4), or ineligibility
by age .65 years at relapse (n 5 1). In the allo versus
no-allo groups, the 3-year NRMs were 22% 6 7%
versus 4% 6 4%, P 5 .005. Univariate analyses indi-
cated that CIR was reduced only by allo in CR1. Mul-
tivariate analysis for CIR indicated that allo was
associated with a reduced risk of relapse (hazard ratioFigure 2. Overall survival (OS) and relapse-free surv[HR], 0.32; 95% confidence interval [CI]: 0.14-0.76;
P5 .01; Table 2). Univariate and multivariate analyses
indicated thatNRMwas increased only by allo in CR1.
Multivariate analysis for NRM is shown in Table 2.
One patient only has undergone transplantation af-
ter day 185 after achievement of CR1, and 6 patients re-
lapsed or died before this date (3 in the allo group and 3
in the no-allo group). By a landmark analysis 185 days
after achievement of CR1, the 3-year CIRs were
19% 6 7% in the allo group versus 57% 6 11% in
the no-allo group (P 5 .003). NRM was 23% 6 8%
in the allo group versus 4%6 4% in the no-allo group
(P 5 .005). The 3-year OS was 57% 6 9% versus
49% 6 11% (P 5 .70) and 3-year RFS was
58% 6 9% versus 39% 6 10% (P 5 .30) in the allo
and no-allo groups, respectively. By multivariate analy-
sis with landmark at day 185, CIR was reduced in the
allo group compared with the no-allo group (HR,
0.23; 95% CI: 0.09-0.59; P 5 .003), and NRM was
higher in the allo group compared with the no-allo
group (HR, 9.9; 95% CI: 1.22-80; P 5 .03).Graft-versus-Host Disease
The 2-year cumulative incidence rates of aGVHD
grade II to IV, aGVHD grade III to IV, and extensive
chronic GVHD were 40% 6 8%, 16% 6 6%, and
25% 6 7%, respectively.DISCUSSION
In the present study, we report a reduced CIR after
RIC-allo as postremission therapy in patients with de
novo IR-AML and an unfavorable genotype. The
high incidence of relapse observed in our study in the
no-allo group is comparable to incidence rates re-
ported in previous studies [6,8,9]. Moreover, the
NRM observed in our study in the allo group is also
comparable to NRM reported in studies focusing on
RIC-allo in myeloid malignancies [19]. During the
most recent years of the study, data on allo withival (RFS) in allogeneic (allo) and no-allo groups.
Figure 3. Cumulative incidence of relapse (CIR) in allogeneic (allo) and
no-allo groups.
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with cord blood, accounting for a higher number of
allo in recent years, and consequently a slightly shorter
follow-up in the allo group. Because only RIC regimes
were used in our study, the reduced incidence of re-
lapse suggests a potent graft-versus-leukemia (GVL)
effect. This benefit did not translate into a difference
in survival because allo was associated with a higher
NRM and because some successful allo procedures
were performed in CR2 in the no-allo group.
The cytogenetic analysis at diagnosis provides
the most powerful independent prognostic factor in
AML [14]. The prognosis has been refined in recent
years by analysis of gene mutations in FLT3, NPM1,
and CEBPA [8,9,20,21]. These efforts have led to the
characterization of IR-AML with a normal karyotype
or cytogenetic aberrations not classified as favorable or
adverse, associated with FLT3-ITD, or triple-negative
genotype [6-9]. The majority of these patients reach
a CR, but a high number rapidly relapse after usual
consolidation therapy with high-dose cytarabine,
accounting for a significant impact on relapse risk and
OS. This adverse effect is more striking in the presence
of a high FLT3-ITD allele ratio indicative of a homozy-
gous mutation [9]. However, this last data has not
been incorporated into the standardized reporting
system for genetic abnormalities recently recommended
from an international expert panel [7]. Naturally, theseTable 2. Results of Multivariate Analyses for CIR and NRM
Variables HR (95% C
Allo (yes versus no) 0.32 (0.14-0.7
WBC at diagnosis (> versus <30,000/mL) 1.27 (0.45-3.5
Karyotype (normal versus abnormal) 1.25 (0.6-2.59
Genotype (FLT3-ITD versus triple-negative) 1.1 (0.4-3.17
Age at diagnosis ($ versus <55 years) 1.85 (0.83-4.1
Courses of chemotherapy to reach CR1 (1 versus $2) 0.64 (0.28-1.4
Year of CR1 (> versus #2006) 0.87 (0.35-2.2
CIR indicates cumulative incidence of relapse; NRM, nonrelapse mortality; HRobservations raise thequestionof theoptimalpostremis-
sion therapy, but prospective studies are lacking.Koreth
et al. [5] reported the results of a systematic review and
meta-analysis of prospective trials evaluating allo versus
non-allogeneic SCT therapies for AML in CR1, based
on donor availability. The risk groups were cytogeneti-
cally defined. They reported that allo had significant
RFS and OS benefit for IR-AML. Most patients were
young, with median ages in the 30s, and underwent
transplantations with an MRD after a myeloablative
conditioning regimen. To further refine the analysis,
Schlenk et al. [6] evaluated the associations of the muta-
tions of the NPM1, FLT3, CEBPA, MLL, and NRAS
genes with clinical outcomes in 872 adults younger
than 60 years of age with cytogenetically normal AML.
In that study, RFS was significantly longer in patients
who underwent transplantation in the subgroup of pa-
tients with the prognostically adverse genotypes
FLT3-ITD or triple-negative. Patients underwent
transplantationwith anMRDafter amyeloablative con-
ditioning regimen. Additionally, Dezern et al. [22] re-
ported the outcome of allo in adult patients under 60
years of age with AML and FLT3-ITD. The study in-
cluded 133 patients. Among them, 31 harbored an
FLT3-ITD mutation at diagnosis. The OS for the
patients with FLT3-ITDwas comparable to the 102 pa-
tients with wild-type FLT3 over the same 4-year time
period. Historically, OS for patients with FLT3-ITD
AML was significantly worse than for patients with
AML lacking this mutation. The authors hypothesized
that the difference that might have contributed to the
surprisingly favorable outcomes for the FLT3-ITD
group was their aggressive pursuit of allo. Altogether,
and despite the lack of prospective data, these studies
suggest that younger patients with FLT3-ITD or
triple-negative IR-AML benefit from myeloablative
allo as postremission therapy. Unfortunately, the avail-
able data do not indicate if this benefit is mostly due to
the antileukemic activity of the conditioning regimen,
or the existence of a potent GVL effect, or both.
A beneficial effect of RIC-allo in older patients
with IR-AML remains uncertain. As summarized in
a recent review article by Storb [19], several authors
have demonstrated the feasibility of RIC-allo in olderCIR NRM
I) P Value HR (95% CI) P Value
6) .01 9.71 (1.18-80) .04
7) .65 0.8 (0.17-3.73) .77
) .56 0.73 (0.23-2.25) .58
) .85 0.74 (0.13-4.22) .73
2) .13 1.41 (0.32-6.13) .65
9) .30 1.47 (0.42-5.17) .54
) .77 0.75 (0.23-2.39) .62
, hazard ratio; CI, confidence interval; Allo, allogeneic.
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reasonable outcomes. That review indicated that 2 to
5-year survival rates of 25% to 64% could be expected,
with similar survival for recipients of related and unre-
lated HLA-matched grafts. Relapse rates ranged from
16% to 53%, and the major issue was NRM ranging
from 16% to 39%. No RIC regimen has proven its
superiority, and fludarabine combined with either
low-dose TBI or an alkylating agent usually leads to
comparable outcome [19]. It must be emphasized
that no study has explored the outcome of RIC-allo
in the specific population of patients with FLT3-ITD
or triple-negative IR-AML. As a consequence, the
benefit of RIC-allo in these patients remains uncertain
to a large extent.
It must be acknowledged that the retrospective na-
ture of our study precludes the declaration of any firm
conclusions. The absence of difference in OS and RFS
must indeed be interpreted with caution given the
modest size of the study. However, we report that
RIC-allo reduces the risk of relapse in patients with
FLT3-ITD or triple-negative IR-AML in CR1, sug-
gesting a potent GVL effect. This finding can be dis-
cussed in light of a recent article suggesting that the
FLT3-ITD-mutated receptor is hyper-responsive to
its cognate ligand rather than autonomously activated
[23]. As chemotherapy leads to high levels of cognate
ligand during the period of recovery and during con-
solidation, the author raises the provocative hypothesis
that successive courses of consolidation chemotherapy
could promote relapse. If this hypothesis is confirmed,
and considering the GVL effect suggested in our
study, the best postremission strategy in patients
with FLT3-ITD could be to proceed as rapidly as pos-
sible to allo once remission is achieved. A strategy of
early allo might also permit the decrease of NRM
and thus improve the outcome of these patients.ACKNOWLEDGMENTS
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